source
- Draig Therapeutics raises $65 million Series B to push depression drug targeting synapse repairDraig Therapeutics announced it has closed a $65 million Series B financing round that was oversubscribed. The capital will be used to advance its neuropsychiatry pipeline, with the lead program f…
- Lyora Therapeutics launches to revive early-stage genetic eye disease programs from Editas and BiogenLyora Therapeutics announced its formation as a new genetic‑medicine company focused on eye diseases. The firm will take over several early‑stage programs that were previously in the pipelines of E…